GSK plc Amends Wave Life Sciences Stake on Dec 31, 2023

TL;DR

**GSK updated its ownership in Wave Life Sciences, signaling continued strategic interest.**

AI Summary

GSK plc, a major pharmaceutical company, filed an amended Schedule 13G/A on February 6, 2024, indicating a change in its beneficial ownership of Wave Life Sciences Ltd. ordinary shares as of December 31, 2023. This filing updates their previous disclosure, showing their continued significant, though potentially adjusted, stake in Wave Life Sciences. This matters to investors because GSK's involvement can signal confidence in Wave Life Sciences' drug development pipeline and future prospects, potentially influencing stock price and market perception.

Why It Matters

GSK's continued reporting of its stake in Wave Life Sciences Ltd. suggests an ongoing strategic interest, which could be a positive signal for Wave Life Sciences' stability and future growth potential.

Risk Assessment

Risk Level: low — This filing is a routine update of a significant shareholder's position and does not inherently introduce new risks.

Analyst Insight

Investors should note GSK's continued presence as a significant shareholder in Wave Life Sciences Ltd. and monitor future filings for any changes in their stake, which could signal shifts in their strategic partnership or investment thesis.

Key Players & Entities

• GSK plc (company) — the reporting person filing the SC 13G/A
• Wave Life Sciences Ltd. (company) — the subject company whose securities are being reported
• December 31, 2023 (date) — the date of the event requiring the filing
• February 6, 2024 (date) — the filing date of the SC 13G/A

FAQ

Key Financial Figures

• $0 — Life Sciences Ltd. (Name of Issuer) $0 Par Value Ordinary Share (Title of Cla

Filing Documents

• wve-sc13ga_123123.htm (SC 13G/A) — 26KB
• 0001999371-24-001596.txt ( ) — 28KB

OWNERSHIP

ITEM 4. OWNERSHIP. The information in items 1 and 5 through 11 on the cover page of this Schedule 13G is hereby incorporated by reference.

OWNERSHIP OF FIVE PERCENT OR LESS OF A

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. Glaxo Group Limited* 13,983,761 11.5% *Shares are held of record by Glaxo Group Limited, an indirect wholly-owned subsidiary of the Reporting Person. 13G/A1 CUSIP No. Y95308105

IDENTIFICATION AND CLASSIFICATION OF THE

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. Not Applicable

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. Not Applicable

NOTICE OF DISSOLUTION OF GROUP

ITEM 9. NOTICE OF DISSOLUTION OF GROUP. Not Applicable

CERTIFICATIONS

ITEM 10. CERTIFICATIONS. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 6, 2024 GSK plc By: /s/ Victoria A. Whyte Victoria A. Whyte Authorized Signatory

View Full Filing

View this SC 13G/A filing on SEC EDGAR